Found 386 oncology trials
A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-Negative Metastatic Triple Negative Breast Cancer (TNBC)
This is a randomized phase 2 open label study of sacituzumab govitecan +/- pembrolizumab for patients with PD-L1-negative (PD-L1-) metastatic triple negative breast cancer (TNBC), who have not received prior therapy for metastatic breast cancer and who have not received a prior PD-1/L1 inhibitor
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation (BRCA-P)
This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. Research has shown that denosumab may also reduce the risk of developing breast cancer in women carrying a BRCA1 germline mutation.
UPCC 52422: A Phase 1 Multicenter Open-Label Dose-Escalation and Expansion Study to Evaluate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas Large Granular Lymphocytic Leukemia and Solid Tumors
Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints)
REVOLUTION: Trial to Evaluate Immunotherapy Combinations with Chemotherapy for the Treatment of Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma
This is a phase 1 study that enrolls subjects with metastatic pancreatic adenocarcinoma. The purpose of this study is to learn about the safety and efficacy of a combination of 4 study drugs: ipilimumab (ipi), nab-paclitaxel (nP), gemcitabine (gem), and hydroxychloroquine (HCQ). This is an open-label, non-randomized, exploratory platform trial …
UPCC 07117: A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
Request for collaborative review: WIRB serving as IRB of record.
UPCC 13118: Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant Palbociclib and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
To evaluate progression-free survival (PFS) using traditional RECIST critiera with the combination of fulvestrant and palbociclib vs. fulvestrant alone in patients with advanced HR+/HER2- breast cancer that has progressed despite prior CDK4/6 inhibition and endocrine therapy.
UPCC 09220: Phase II Study of Telomelysin (OBP-301) in Combination with Pembrolizumab in Esophagogastric Adenocarcinoma
The purpose of this study is to test the effects of the research study drug Telomelysin (OBP-301) in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer. Eligible subjects are those with advanced or metastatic cancer of the stomach or junction between the stomach and esophagus.
Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)
This is a prospective natural history study of CIPN in approximately 200 participants receiving taxanes (paclitaxel, docetaxel) for breast cancer or vincristine for lymphoma. Participants will be enrolled over approximately 1-year.The purpose of this present study is to prospectively collect clinical and biomarker data from patients receiving neurotoxic chemotherapy who …
Study to Evaluate the Safety Tolerability and Preliminary Efficacy of XmAb 20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer
The primary purposes of this research study are to determine the safety and tolerability of XmAb20717 by itself and in combination with other anticancer therapies. Subjects are being asked to take part in this research study because they have metastatic castration resistant prostate cancer (mCRPC), a prostate cancer that has …
Study of JNJ-75229414 a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).
Please choose between Voice or SMS based delivery of verification code
or